Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.

14 The study further demonstrated a nominally significant reduction in the exploratory composite endpoint of all‐cause death, cardiovascular hospitalizations, or emergency presentation for worsening HF with finerenone compared with eplerenone. 14 Patients with symptomatic HFrEF, who have a class IA indication for MRA therapy, were excluded from the FIDELIO‐DKD trial. 11 As a result, patients with a history of HF at baseline studied in this analysis were likely to have asymptomatic HFrEF (LV ejection fraction [LVEF] <40%) or HFrEF with NYHA class I, HFpEF (LVEF ≥50%), or HFmrEF (LVEF 40%–49%).

also in 7,732 other papers